TD Cowen raised the firm’s price target on Insmed (INSM) to $193 from $154 and keeps a Buy rating on the shares. The firm noted the company presented its impressive Ph2 PAH data with TPIP as late breaker. EPs show TPIP improved hemodynamic parameters, suggesting favorable impacts on heart function and supports the pulmonary selectivity of TPIP.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed’s TPIP Shows Promising Phase 2 Results, Boosting Buy Rating and Future Prospects
- Insmed price target raised to $180 from $110 at Evercore ISI
- Measured Optimism and Caution: Maxwell Skor’s Hold Rating on Insmed Amid Promising Brinsupri Launch
- Insmed to present multiple abstracts from ERS Congress 2025
- Promising Market Potential for Insmed’s Brensocatib Drives Buy Rating